Muscle Atrophy Clinical Trials

Find Muscle Atrophy Clinical Trials Near You

Muscle Aging Phenotypes in Childhood Cancer Survivors

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Objective: \- Characterize reduced muscle health endotypes in childhood cancer survivors. Secondary Objective: \- Identify specific treatment and lifestyle related risk factors for each reduced muscle health endotype. Exploratory Objective: \- Host germline genetics will be associated with specific muscle endotypes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Age 18 years old or older at time of consent and enrolled in SJLIFE.

• Participant (100 per group for a total of 400) is/has:

• Group 1: No cancer history

• Group 2: Age and sex specific relative lean mass z-score of less than -0.5 OR age and sex specific hand grip or isokinetic (60 degrees/sec) quadriceps strength z-score of \<-0.5 AND exposure to a peripheral neurotoxin.

• Group 3: Age and sex specific relative lean mass z-score of less than -0.5 OR age and sex specific hand grip or isokinetic (60 degrees/sec) quadriceps strength z-score of \<-0.5 AND NOT exposed to a peripheral neurotoxin.

• Group 4: Age and sex specific relative lean mass z-score of less than -0.5 AND age and sex specific hand grip strength or isokinetic (60 degrees/sec) quadriceps strength z-score of \<-0.5 REGARDLESS of exposure status.

• Participant or legal guardian is able and willing to give informed consent.

Locations
United States
Tennessee
St. Jude Children's Research Hospital
RECRUITING
Memphis
Contact Information
Primary
Kirsten Ness, PhD
referralinfo@stjude.org
888-226-4343
Time Frame
Start Date: 2026-10-01
Estimated Completion Date: 2031-05
Participants
Target number of participants: 533
Treatments
Community Controls
Adults with no history of cancer recruited from the community or non-first-degree relatives of St. Jude patients.
Survivors With Low Lean Mass or Weakness and Peripheral Neurotoxin Exposure
Adult childhood cancer survivors with low lean mass and/or muscle weakness and documented exposure to peripheral neurotoxic therapies.
Survivors With Low Lean Mass or Weakness Without Peripheral Neurotoxin Exposure
Adult childhood cancer survivors with low lean mass and/or muscle weakness and no history of exposure to peripheral neurotoxic therapies.
Survivors With Low Lean Mass and Muscle Weakness (Regardless of Neurotoxin Exposure)
Adult childhood cancer survivors meeting criteria for both low lean mass and muscle weakness, irrespective of treatment exposure.
Related Therapeutic Areas
Sponsors
Leads: St. Jude Children's Research Hospital
Collaborators: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov